Fresenius Kabi

Fresenius Kabi is a global healthcare company and an operating company of the Fresenius Group, focused on therapies and care for critically and chronically ill patients. Its portfolio spans intravenous medicines and fluids, clinical nutrition, medical technologies, and biopharmaceuticals, with products used across emergency medicine, surgery, oncology, intensive care, and home care. The company positions itself as a provider of essential, high-quality healthcare solutions that help make complex therapies simpler, safer, and more accessible. Its website emphasizes patient centricity, quality, innovation, and close collaboration with healthcare professionals to support better outcomes across the continuum of care. Core Values Patient centricity : Fresenius Kabi frames its work around the needs of critically and chronically ill patients, aiming to improve quality of life and support caregivers with practical, reliable solutions. Quality and safety : The company stresses no-compromise quality, regulatory compliance, product safety, and structured quality management as foundations for trust in its products and services. Innovation : Fresenius Kabi highlights continuous innovation in medicines, devices, and therapies, including ready-to-administer formats, smart infusion systems, and biosimilars. Collaboration : The company emphasizes working closely with healthcare professionals, customers, suppliers, and partners to improve products and deliver better care. Sustainability and responsibility : Its sustainability messaging focuses on reducing environmental impact, using resources responsibly, and acting today for a better tomorrow. Unique Aspects Part of the Fresenius Group : Fresenius Kabi operates within the broader Fresenius Group, which gives it scale, financial backing, and access to a global healthcare platform. Major biosimilars expansion through mAbxience : In 2022, Fresenius Kabi acquired a majority stake in mAbxience, strengthening its vertically integrated biosimilars platform and expanding manufacturing and CDMO capabilities. Ivenix acquisition and smart-pump capability : The 2022 acquisition of Ivenix added advanced infusion technology to the portfolio, including smart pumps with connectivity to hospital information systems and electronic medical records. Global transfusion leadership : The company’s heritage includes the Fenwal acquisition, which helped create a global leader in transfusion technology and blood collection systems. Broad international reach : Fresenius Kabi says its products are used in more than 100 countries, and its portfolio reaches hundreds of millions of patients annually.